Overcoming Biological Barriers: A Review of Nanomedicine Strategies for Crossing the Blood-brain Barrier in Neuro-oncology

Abstract

The formidable challenge of crossing the blood-brain barrier (BBB) remains a critical impediment to effective drug delivery for neuro-oncological diseases. This protective mechanism severely restricts the passage of therapeutic agents, necessitating innovative strategies to achieve sufficient drug concentrations within the brain. This review comprehensively examines the latest advancements in nanomedicine designed to overcome this significant biological obstacle. We explore the fundamental structure and function of the BBB to establish a foundation for understanding nanocarrier design principles. The review details key nanomedicine approaches, including the use of cell-penetrating peptides, biologically-derived nanomaterials, and receptor-mediated transcytosis to facilitate targeted delivery. Furthermore, we discuss how critical physicochemical properties—such as nanoparticle size, surface charge, and functionalization—dictate barrier penetration efficacy. The integration of multifunctional platforms that combine therapeutic and diagnostic capabilities is also highlighted. The discussion is supported by an analysis of recent preclinical studies and clinical translations that demonstrate promising outcomes. Finally, we address the persistent challenges of scalability, biocompatibility, and long-term toxicity that accompany these emerging technologies. Future progress in this field hinges on the development of advanced biomimetic nanocarriers and precision-targeting strategies to improve specificity and reduce off-target effects. Overcoming translational bottlenecks through standardized evaluation protocols and comprehensive safety profiling will be essential for clinical adoption. Ultimately, continued interdisciplinary collaboration is vital to fully realize the potential of nanomedicine in revolutionizing the treatment of brain cancers and other neurological disorders.